/Biogen%20Inc%20logo%20on%20HQ-by%20Tada%20Images%20via%20Shutterstock.jpg)
Biogen Inc. (BIIB) is one of the world’s leading biotechnology companies. Valued at $32.5 billion by market cap, the company pioneers therapies for neurological and neurodegenerative diseases globally. Renowned for breakthroughs like TECFIDERA, SPINRAZA, ADUHELM, and OCREVUS, Biogen leads in treating MS, Alzheimer's, and more. Its robust pipeline includes innovations for Parkinson's, neuropsychiatric disorders, and biosimilars. Collaborations with Acorda, Denali, and Genentech bolster its research prowess. Founded in 1978, Biogen continues to push boundaries from its Cambridge, Massachusetts headquarters, shaping the future of neurology and immunology with cutting-edge treatments and partnerships.
Companies worth $10 billion or more are generally described as “large-cap stocks,” Biogen fits that category, boasting a market cap that exceeds this threshold, reflecting its size, significant influence, and dominance in the biotech industry. Biogen became a large-cap stock through pioneering biotech breakthroughs and strong market performance in neurology and immunology, attracting investor confidence and boosting its market cap.